Fluctuations in volume and sentiment are key signals that investors watch when identifying new opportunities. Lately, a number of healthcare stocks have seen a rise in trading activity, highlighting a surge in engagement from the market. This development implies that attention may be turning toward companies that have not yet been in the spotlight.
Zentek Ltd (ZTEK)
Zentek Ltd (NASDAQ: ZTEK) opened the trading on April 22, 2026, with a bit cautious approach as it glided -4.18% to $0.5. During the day, the stock rose to $0.52 and sank to $0.49. Taking a more long-term approach, ZTEK posted a 52-week range of $0.46-$1.84.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 35.94%. Meanwhile, its Annual Earnings per share during the time were -35.94%. This publicly-traded company’s shares outstanding now amount to $107.37 million, simultaneously with a float of $102.98 million. The organization now has a market capitalization of $53.24 million.
Prenetics Global Limited (PRE)
Prenetics Global Limited (NASDAQ: PRE) started the day on April 22, 2026, with a price decrease of -0.11% at $17.96. During the day, the stock rose to $18.64 and sunk to $17.81. Taking a more long-term approach, PRE posted a 52-week range of $4.30-$23.63.
It was noted that the giant of the Healthcare sector posted annual sales growth of 27.19% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 27.19%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.95%. This publicly-traded company’s shares outstanding now amounts to $16.83 million, simultaneously with a float of $12.05 million. The organization now has a market capitalization sitting at $302.24 million.
Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) is expanding its long-term growth profile through a pipeline strategy that extends beyond its lead asset into larger, high-value cardiovascular markets. By advancing next-generation therapies, the company is positioning itself to capture opportunities in conditions with significant unmet need, particularly heart failure.
Market Momentum
As of April 22, 2026, CRDL closed at $1.51, plunging 7.36%, with trading volume (1.16M shares) significantly above its average of 654,693 shares—indicating elevated activity during the pullback. With a market cap of $168.637M, the stock remains within its 52-week range ($0.8800–$1.71). A 1-year target estimate of $7.45 continues to reflect meaningful upside potential as development programs progress.
Pipeline Expansion: CRD-38
The company is developing CRD-38, a subcutaneous therapy designed for more convenient dosing and broader clinical application, particularly in heart failure. This next-generation asset targets both inflammation and fibrosis, key drivers of disease progression that are not adequately addressed by current therapies.
Market Opportunity
Heart failure represents a multi-billion-dollar global market with millions of patients and limited treatment options targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter a large and underserved segment, significantly expanding its potential addressable market beyond pericarditis and myocarditis.
Outlook
As CRD-38 progresses toward clinical development, it could become a key value driver for the company. Success in this program would enhance Cardiol’s long-term growth trajectory and support its evolution into a more diversified cardiovascular innovator.